Bupropion (Wellbutrin) for Adult ADHD
Bupropion is a second-line medication for adult ADHD, reserved for patients who have failed or cannot tolerate stimulants, or when active substance use disorder is present. 1
Position in Treatment Algorithm
Stimulants remain the gold standard first-line treatment for adult ADHD, with 70-80% response rates and the largest effect sizes (≈1.0) from over 161 randomized controlled trials. 1 Bupropion should only be considered after:
- Two or more adequate stimulant trials have failed (both methylphenidate and amphetamine classes should be tried, as approximately 40% of patients respond to only one class) 1
- Intolerable stimulant side effects persist despite dose adjustments 1
- Active substance use disorder is present, though atomoxetine or alpha-2 agonists are actually preferred in this scenario due to zero abuse potential 1
- Comorbid depression exists and you wish to address both conditions, though the evidence shows no single antidepressant effectively treats both ADHD and depression simultaneously 2
Efficacy Evidence
Bupropion demonstrates modest efficacy for ADHD with an effect size of approximately 0.7, which is lower than stimulants (effect size ≈1.0) but comparable to atomoxetine. 1, 3
- A Cochrane systematic review found low-quality evidence that bupropion decreased ADHD symptom severity (standardized mean difference -0.50) and increased the proportion achieving clinical improvement (risk ratio 1.50) compared to placebo 3
- Response rates in controlled trials ranged from 42-76% for bupropion versus 24-37% for placebo 4
- The effect size of 0.6-0.7 indicates moderate therapeutic benefit, but falls short of stimulant efficacy 5, 6
The evidence quality is limited by small sample sizes, short trial durations (6-10 weeks), and lack of long-term outcome data. 3
Dosing and Administration
Start bupropion XL at 150 mg once daily in the morning; after 4-7 days, increase to the target dose of 300 mg once daily. 7
- The FDA-approved maximum dose is 450 mg daily, though doses above 300 mg were not specifically assessed in ADHD trials 7
- Bupropion SR can be dosed 100-150 mg twice daily, titrated to 150-300 mg daily 2
- Tablets must be swallowed whole and not crushed, divided, or chewed to maintain extended-release properties and reduce seizure risk 7
- May be taken with or without food 7
- Onset of therapeutic effect is more rapid than atomoxetine (which requires 6-12 weeks) but slower than stimulants (which work within days) 1, 2
Safety and Monitoring
Baseline Assessment
- Screen for seizure history, eating disorders, or abrupt alcohol/benzodiazepine discontinuation (all increase seizure risk) 7
- Obtain baseline blood pressure and pulse 1
- Screen for suicidality, particularly when comorbid depression exists 1
Ongoing Monitoring
- Blood pressure and pulse at each visit, though cardiovascular effects are less pronounced than with stimulants 1
- Suicidality screening at every visit, especially during the first few months or at dose changes (FDA black-box warning for increased suicidal ideation in patients <24 years) 7
- Seizure risk increases at doses >450 mg/day (approximately 0.1% at therapeutic doses, rising to 0.4% at 450 mg) 7
Common Adverse Effects
- Headache, insomnia, and anxiety are the most frequent side effects 1, 2
- Appetite suppression and weight loss (which may be beneficial in some patients) 2
- Agitation or activation, which can worsen hyperactivity in some patients 2
Contraindications
- Seizure disorder or conditions that increase seizure risk (eating disorders, abrupt benzodiazepine/alcohol withdrawal) 7
- Concurrent MAOI use or within 14 days of MAOI discontinuation (risk of hypertensive crisis) 2, 7
- Bulimia or anorexia nervosa 7
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs 7
Special Populations
Substance Use Disorder
Bupropion is not a controlled substance and has no abuse potential, making it theoretically attractive for patients with substance use history. 7 However, atomoxetine or alpha-2 agonists are preferred first-line non-stimulants in this population. 1
- Animal studies show bupropion exhibits some psychostimulant-like properties (increased locomotor activity, mild amphetamine-like effects at high doses) 7
- Intranasal or intravenous abuse has been reported, with associated seizures and deaths 7
- Higher doses might be modestly attractive to CNS stimulant abusers, though recommended oral doses are unlikely to be significantly reinforcing 7
Comorbid Depression
When both ADHD and depression are present, the recommended approach is to start with a stimulant for ADHD, then add an SSRI if depressive symptoms persist after 6-8 weeks of optimized ADHD treatment. 2
- No single antidepressant, including bupropion, is proven to effectively treat both ADHD and depression simultaneously 2
- Bupropion may be particularly useful when depression is comorbid, but should not be relied upon as monotherapy for both conditions 1
- If ADHD symptoms improve but mood symptoms persist, adding an SSRI to the stimulant regimen is preferred over switching to bupropion 2
Pregnancy and Lactation
- Bupropion does not appear to be associated with major congenital malformations 1
- Possible small increased risks for cardiac malformations and preeclampsia have been reported in some studies 1
- Risk-benefit assessment should balance medication exposure against the documented hazards of untreated ADHD (spontaneous abortion, preterm birth, functional impairment) 1
Renal Impairment
Consider reduced dose and/or dosing frequency in patients with renal impairment (GFR <90 mL/min), as bupropion and its metabolites are cleared renally. 7
Hepatic Impairment
- Maximum dose is 150 mg every other day in moderate to severe hepatic impairment (Child-Pugh score 7-15) 7
- Consider reducing dose and/or frequency in mild hepatic impairment (Child-Pugh score 5-6) 7
Clinical Pitfalls to Avoid
Do not prescribe bupropion as first-line therapy without adequate stimulant trials. Approximately 70-80% of patients respond to properly titrated stimulants, and trying both methylphenidate and amphetamine classes is essential before moving to second-line agents. 1
Do not assume bupropion will effectively treat both ADHD and depression. The evidence explicitly states no single antidepressant is proven for this dual purpose. 2
Do not use bupropion in patients with prominent hyperactivity or anxiety. Bupropion is inherently activating and can exacerbate these symptoms. 2
Do not exceed 450 mg daily due to dose-dependent seizure risk. 7
Do not combine with MAOIs or start within 14 days of MAOI discontinuation. 2, 7
Do not crush, divide, or chew extended-release formulations, as this increases seizure risk and destroys the extended-release mechanism. 7
Comparison to Other Non-Stimulants
Atomoxetine is generally preferred over bupropion as the first non-stimulant option for adult ADHD. 1
- Atomoxetine is the only FDA-approved non-stimulant for adult ADHD 1
- Both have similar effect sizes (≈0.7) 1
- Atomoxetine provides 24-hour coverage and has no abuse potential 1
- Atomoxetine requires 6-12 weeks for full effect versus bupropion's more rapid onset 1
- Atomoxetine carries an FDA black-box warning for suicidal ideation, requiring intensive monitoring 1
Alpha-2 agonists (guanfacine, clonidine) are alternative non-stimulants with effect sizes around 0.7, particularly useful when comorbid tics, sleep disturbances, or anxiety are present. 1
Summary Recommendation
Bupropion XL 150-300 mg daily is a reasonable second-line option for adult ADHD after adequate stimulant trials have failed, with particular consideration when comorbid depression or smoking cessation is a treatment goal. 1, 3 However, its modest effect size (0.7 versus 1.0 for stimulants), lack of FDA approval for ADHD, and potential for activation/anxiety limit its role to specific clinical scenarios where first-line treatments are inappropriate or ineffective.